Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Versus placebo, pemafibrate yielded a more than 25% greater reduction in triglycerides, VLDL, remnant cholesterol, and apolipoprotein C-III in patients with type 2 diabetes. However, there was no reduction versus placebo in MI, ischemic stroke, need for coronary revascularization, or CV death.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form